Russian government to allow production of anti-HIV drugs bypassing patent-holders rights

8 March 2017

The Russian government is ready to allow the production of anti-HIV drugs bypassing patents of their right-holders, reports The Pharma Letter’s local correspondent.

This will be in the form of the federal law, that will officially come into a force on July 1 of the current year, and will provide the power to the national government to establish the procedure for issuing permits for use of a the drug and its production within Russia without the consent of the patent holder.

In recent years Russia has faced with epidemics of HIV infection, however the government does not have the necessary amount of funds to ensure the purchases needed medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK